In honor of the annual World Lung Cancer Day commemoration on Aug. | In honor of the annual World Lung Cancer Day ...

Despite the overall decline in commercial product revenue, Moderna was also pleasantly surprised by Q2 Spikevax sales, which ...

Over a whirlwind three weeks, Sarepta Therapeutics has faced tough safety questions around its commercial gene therapy ...

Lenz Therapeutics has earned the FDA’s go-ahead for its aceclidine eye drop to crack the large presbyopia market, where past ...

GSK signed a 12-asset licensing deal with Hengrui Pharma. Generic erosion on Vyvanse continued to hurt Takeda. Celltrion is ...

But this time, the unknown is hitting the industry in a different way from when Prasad was tapped to lead CBER less than ...

Despite efforts to spare employees by scaling back R&D and reducing operating costs by roughly $1.5 billion over the next two ...

As pharmaceutical import tariffs take shape in Europe, President Donald Trump is rounding out the week by spotlighting ...

Regeneron-partnered Dupixent, the crown jewel of Sanofi’s commercial portfolio, continued to impress with 21.1% sales growth ...

After beating quarterly earnings expectations and raising its full-year sales outlook from a previously forecast decline, ...

As for its neuroscience portfolio, AbbVie has added $300 million, putting its projection for the year at $10.5 billion, which ...

Vinay Prasad, M.D., has left the FDA less than three months into the role as director of the Center for Biologics Evaluation ...